ODS 2004436Alternative Names: ODS-2004436
Latest Information Update: 24 Aug 2016
At a glance
- Originator Oncodesign Biotechnology
- Developer Centre Georges Francois Leclerc; Oncodesign Biotechnology
- Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Phosphotransferase inhibitors; Positron-emission tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lung cancer